Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.41 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL4045692 | 0.90 | SLC7A5 (0.71) | SLC7A5LCKPPARDZDHHC20ZDHHC2 | |
| Dodecane SCHEMBL28109673 | 0.88 | SLC7A5 (0.68) | SLC7A5LCKPPARDZDHHC20ZDHHC2 | |
| Valine SCHEMBL11005807 | 0.88 | SLC7A5 (0.68) | SLC7A5LCKPPARDZDHHC20ZDHHC2 | |
| Valine SCHEMBL28555130 | 0.82 | SLC7A5 (0.60) | SLC7A5GRIK1GRIK2SLC1A2SLC1A1 | |
| Valine SCHEMBL11876966 | 0.81 | SLC7A5 (0.79) | SLC7A5GRIK1GRIK2SLC1A2SLC1A1 | |
| Tetrabuthylammonium SCHEMBL18878889 | 0.81 | SLC7A5 (0.58) | SLC7A5GRIK1GRIK2SLC1A2SLC1A1 | |
| Valine SCHEMBL2383315 | 0.81 | SLC7A5 (0.58) | SLC7A5LCKPPARDZDHHC20ZDHHC2 | |
| Tetrabuthylammonium SCHEMBL18878892 | 0.81 | SLC7A5 (0.58) | SLC7A5GRIK1GRIK2SLC1A2SLC1A1 | |
| Valine SCHEMBL786889 | 0.81 | SLC7A5 (0.58) | SLC7A5PPARDGPR84FFAR1MAPT | |
| Valine SCHEMBL27206170 | 0.81 | SLC7A5 (0.58) | SLC7A5LCKPPARDZDHHC20ZDHHC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240124394-A1 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2024-04-18 | — | — | US | disclosed |
| EP-4267117-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116685313-A | Indanyl-containing carboxylic acid compounds for the treatment of neurodegenerative diseases | 细胞基因公司 | 2023-09-01 | — | — | CN | disclosed |
| WO-2023107592-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-4161926-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Yumanity Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2022140555-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-104066727-B | Methyl fluoride -5,6- dihydro -4H- [1,3] oxazines class | 霍夫曼-拉罗奇有限公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-103380134-B | N-[3-(5-amino-3,3A, 7,7A-tetrahydrochysene-1H-2,4-dioxa-6-azepine-indenes-7-base)-phenyl]-amide as BACE1 and/or BACE2 inhibitor | 霍夫曼-拉罗奇有限公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-104066727-A | Fluoromethyl-5,6-dihydro-4H-[1,3]oxazines | HOFFMANN LA ROCHE | 2014-09-24 | — | — | CN | disclosed |
| US-6964983-B2 | Compounds that modulate PPAR activity and methods for their preparation | WARNER-LAMBERT COMPANY, LLC (US) | 2005-11-15 | — | — | US | disclosed |
| US-6939875-B2 | Carbocyclic oxy sulfides such as [4-(Biphenyl-4-ylmethylsulfanyl)-5-methoxy-2-methyl-phenoxy]-acetic acid, used to control peroxisome proliferator activated receptors (PPAR), for prophylaxis of metabolic disorders | WARNER-LAMBERT COMPANY (US) | 2005-09-06 | — | — | US | disclosed |
| CN-1649820-A | Compounds that modulate PPAR activity and methods for preparing the same | WARNER LAMBERT CO (US) | 2005-08-03 | — | — | CN | disclosed |
| US-20050153996-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | AUERBACH BRUCE J (US) | 2005-07-14 | — | — | US | disclosed |
| US-20050113440-A1 | Compounds that modulate PPAR activity and methods for their preparation | AUERBACH BRUCE J (US) | 2005-05-26 | — | — | US | disclosed |
| EP-1494989-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20030225158-A1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER-LAMBERT COMPANY | 2003-12-04 | — | — | US | disclosed |
| WO-2003084916-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-16 | — | — | WO | disclosed |
| US-5223539-A | Antagonist of platelet activating factor | G. D. SEARLE & CO. (US) | 1993-06-29 | — | — | US | disclosed |
| WO-1993010077-A1 | N,N-DI-ALKYL(PHENOXY)BENZAMIDE DERIVATIVES | G.D. SEARLE & CO. (US) | 1993-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | PNPO, DPYD, PYGB | SLC7A5 2837/4885LCK 2187/4885PPARD 1531/4885 |
| US-20030225158-A1 | Compounds that modulate PPAR activity and methods for their preparation | GPR119, PPARA, PPARG | SLC7A5 2814/4885LCK 2838/4885PPARD 4/4885 |
| US-20050113440-A1 | Compounds that modulate PPAR activity and methods for their preparation | GPR119, PPARA, PPARG | SLC7A5 2814/4885LCK 2838/4885PPARD 4/4885 |
| US-20050153996-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | GPR119, PPARA, PPARG | SLC7A5 2814/4885LCK 2838/4885PPARD 4/4885 |
| US-20240124394-A1 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, S1PR2, LPAR5 | SLC7A5 974/4885LCK 2281/4885PPARD 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.